Regulating mitochondrial donation: seeking expert views. Background document
|
|
- Delphia Goodman
- 6 years ago
- Views:
Transcription
1 Regulating mitochondrial donation: seeking expert views Background document June 2015
2 Contents Introduction 3 What we need from you 3 Licensing mitochondrial donation 4 Licensing the clinic to undertake mitochondrial donation 4 Individual patient approval 5 Questions to consider 6 Best practice guidance and other requirements 7 Mitochondrial donor screening 7 Age limit for mitochondrial donors 7 The 10 family limit 7 Consent and information provision 8 Questions to consider 9 Follow-up studies 10 Question to consider 10 Regulating mitochondrial donation: seeking expert views 2
3 Introduction Researchers are developing medical techniques, known as mitochondrial donation, that could allow mothers to avoid passing on genetically inherited mitochondrial diseases to their children. The most developed techniques, maternal spindle transfer (MST) and pro-nuclear transfer (PNT), involve a patient going through an IVF cycle but with additional steps. In both MST and PNT, nuclear DNA (the vast majority of genes in a cell, which make us who we are) is moved from a patient s egg or embryo containing unhealthy mitochondria to a donor s egg or embryo containing healthy mitochondria. The nuclear DNA has been removed from the donor s egg or embryo before this process takes place. You can find out more about these techniques on our website. In February 2015 Parliament approved regulations to permit MST and PNT to avoid serious mitochondrial disease. The regulations, which come into force on 29 October 2015: modify the definition of permitted egg and permitted embryo in the Human Fertilisation and Embryology Act to allow an egg or embryo created by MST or PNT to be used in treatment set out the process and circumstances that must be met for a clinic to perform MST or PNT, and introduce a different system for providing information to children conceived from mitochondrial donation. Over the last four years, we have looked extensively at public attitudes towards mitochondrial donation and their safety and efficacy (see a summary on our website). Now we are designing a system to regulate and license mitochondrial donation so that clinics wishing to carry out these treatments can apply for permission to do so. What we need from you This document summarises our plans for regulating and licensing mitochondrial donation and asks for your feedback on key areas relating to: the licensing process policy issues, and follow-up studies. Once you ve read about our plans in this document, please complete our online survey by 6 July 2015 to give us your views. We will also be holding a workshop on 23 June 2015 where you can give us your views in person. It s important to point out that we are not asking you to comment on the wider ethical and scientific issues involved, nor the statutory framework. We are asking for your help to finalise the system we will use to regulate and license mitochondrial donation, ready for when the regulations come into force. Regulating mitochondrial donation: seeking expert views 3
4 Licensing mitochondrial donation The licensing process has two stages: the licensing of a clinic to undertake mitochondrial donation, and the authorisation to undertake the treatment in the case of a particular patient (individual patient approval). Our scientific panel recommended that, before the first clinical case of MST or PNT can happen, further experiments should be carried out. 1 Once our board ( the Authority ) is made aware that these essential experiments have been completed, we will convene an expert panel to make an assessment of the safety and efficacy of these techniques. The Authority will receive this panel s report. If it decides that the techniques are safe and effective enough to be used in clinical practice, any clinic wishing to use the technique clinically can apply for a licence and will need to follow the process outlined below. This would only need to be done once, presuming that the techniques are shown to be safe. Licensing the clinic to undertake mitochondrial donation Before any HFEA-licensed clinic can undertake mitochondrial donation for treatment purposes, it will need to apply to us to vary its licence to include the necessary express provision to carry out MST and/or PNT. This will follow the same process as a clinic applying to vary its licence for other purposes (such as the addition of embryo testing) ie, by way of an application to our Licence Committee. As part of this process, the clinic will need to submit to us the necessary evidence to demonstrate the competence of the clinic staff and suitability of its premises and processes with specific reference to PNT and/or MST. All staff either directly involved in mitochondrial donation techniques, or staff involved with patients receiving such treatment, must be suitably qualified, trained and assessed as competent for the tasks they perform. For example, we propose that clinics will need to demonstrate the competence of their clinical embryologists to perform mitochondrial donation techniques, by submitting: information about their experience of performing micro-manipulation on human or animal (eg, mice) eggs or embryos information on their specific experience of carrying out MST and/or PNT in treatment, training or research references to support their experience and knowledge, and any other information that may demonstrate competence. Evidence will also be required of suitable validation of equipment and processes. We propose that the whole process of MST/PNT, including the transfer of embryos to the woman, must be carried out at a clinic specifically licensed to carry out that technique. 1 See Third scientific review of the safety and efficacy of methods to avoid mitochondrial disease through assisted conception: 2014 update. Regulating mitochondrial donation: seeking expert views 4
5 Individual patient approval Before a clinic licensed to do MST and/or PNT is permitted to carry out the treatment for a specific patient, it will need to apply to our Statutory Approvals Committee (SAC) for approval. If granted, approval can only be given for the treatment to be applied to the particular patient, in the circumstances described in the regulations. The regulations prescribe the circumstances in which either MST or PNT can be applied to an egg or embryo. Step one of the approval is the assessment of whether there is a particular risk of the egg or embryo having a mitochondrial abnormality caused by mitochondrial DNA. The biology of mitochondrial disease means that for any woman carrying mutant mitochondrial DNA (mtdna), even if only a few molecules of affected mtdna are present, there is almost a 100% risk that her eggs will have mitochondrial abnormalities caused by mitochondrial DNA. We therefore propose that the presence of a mutation in the female patient s mtdna alone is sufficient to satisfy the test for particular risk. The second step is the assessment of whether there is a significant risk that a child with those abnormalities will have, or develop, a serious mitochondrial disease. In order for us to assess significant risk, we propose asking clinics to submit evidence on the scientific literature, family history and patient history. Clinicians will be able to submit other evidence that in their view may be relevant to the assessment of significant risk. When making an assessment of seriousness we propose that this should be made, where possible, based on the most severe symptoms that could be expected for a particular case. To support an application, a clinic will need to submit patient-specific information on: the patient s mutant mtdna load and mutation threshold the patient s medical history the patient s family medical history of the mtdna mutation or disease scientific literature relevant to the mtdna mutation or disease, and any additional information which the clinician may consider is relevant to the application. Regulating mitochondrial donation: seeking expert views 5
6 Questions to consider We ve set out what we propose to do. Now we want to hear your views about some specific issues on the individual patient approval process. 1. Before a clinic can be licensed to carry out PNT and/or MST they must be able to demonstrate they have the necessary skills and competency. Do you think the proposed approach for assessing the competency of a clinical embryologist is appropriate? Do you have any suggestions for alternative or additional evidence that could demonstrate the competency of a clinical embryologist intending to perform one or both of these techniques? 2. Before a clinic licensed to do MST and/or PNT is permitted to carry out the treatment for a specific patient, the patient s case must satisfy criteria outlined in the regulations. a) MST and/or PNT can only be carried out for a specific patient where there is a particular risk of the egg or embryo having a mitochondrial abnormality caused by mitochondrial DNA. Do you think the proposed approach for assessing the particular risk by reference to the presence of mutant mitochondria is appropriate? Please provide details of any other relevant measures, evidence, or criteria that could be used to determine the presence of a particular risk (please refer to p5 of this document). b) Does this proposed process take into account all aspects relevant to the risk, and seriousness, of the disease and mitochondria disease biology? Please provide details of any other relevant information that could support an application for a particular patient. Regulating mitochondrial donation: seeking expert views 6
7 Best practice guidance and other requirements We propose making a number of changes to our guidance and requirements to cover the use of mitochondrial donation in clinical treatment. We would like to hear your views on: mitochondrial donor screening age limit for mitochondrial donors the 10 family limit consent and information provision. Mitochondrial donor screening Mitochondrial donors will provide their eggs in the same way as egg donors for treatment (the same will apply to men who provide sperm used in the PNT process). As their eggs will be processed and used to create embryos, the risk of infectious diseases being transmitted is likely to be the same. Therefore, most of the same requirements for laboratory tests and storage set out in licence condition T52 in relation to sperm and egg donors will apply to mitochondrial donors, except for genetic screening (for autosomal recessive genes known to be prevalent, according to international scientific evidence, in the donor s ethnic background). It will also be relevant to assess mitochondrial donors medical history and the risk of transmitting inherited conditions known to be present in the family, which could possibly be inherited by mitochondrial DNA. Age limit for mitochondrial donors Age will be an important consideration when selecting mitochondrial donors as the mitochondrial DNA has a very high mutation rate resulting in numerous new mutations over a person s lifetime, and potentially resulting in decreased mitochondrial function. The age of the donor may also affect the number of viable eggs that are collected. We are proposing that the guidelines on the age limit for egg donors should apply to mitochondrial donors. Professional guidelines state that eggs should not be taken from donors aged 36 or over. We propose to advise clinics to observe this age limit unless there are exceptional reasons. The 10 family limit The family limit refers to the number of families a single donor can help to create. The current limit is based on the perceived social and psychological interests of donors and donor-conceived people in maintaining a relatively small number of siblings/children. It is also there to minimise the possibility of two children from the same donor having a relationship with each other without knowing they are genetically related. We propose that the 10 family limit should also apply to women donating their mitochondria. In the case of a woman who donates eggs for treatment and mitochondrial donation, she can only donate to a total of 10 families across both types of donation. You could argue that the reasons for setting the limit at 10 (as outlined above) do not apply in the same way to children born from mitochondrial donation. However, we think that the Regulating mitochondrial donation: seeking expert views 7
8 number of offspring from one donor should be kept low to reduce the risk of one of those donors later being found to have a transmissible disease or condition. It is our current understanding that limiting the amount of families a mitochondrial donor can donate to to 10 is unlikely to have much impact, as very few egg donors go through enough egg donation cycles to donate to this number of families. Consent and information provision Our Code of Practice (guidance note 4) sets out the information that should be provided to patients before consent is obtained (eg, information about the clinic s waiting times, potential risks, likely outcomes etc). We propose that before clinics obtain consent they should provide patients with information about the potential risks of mitochondrial donation, the importance of follow-up studies and encouraging openness with any resulting children. Guidance note 11 in our Code of Practice sets out the information that should be provided to prospective sperm, egg and embryos donors before their consents or samples are taken (eg, information about the screening that will be done and why it is necessary). We propose that good practice regarding sperm and egg donation should apply equally to mitochondria donation. Best practice around information provision regarding unsuspected heritable conditions in donors should also apply to mitochondria donors. This would mean that if a clinic learns, through the birth of an affected child, that a mitochondria donor carries a previously unsuspected mitochondrial disease, then the donor should be notified (if they have indicated that they wish to be notified). Regulating mitochondrial donation: seeking expert views 8
9 Questions to consider We ve set out what we propose to do. Now we want to hear your views about some specific policy issues. 3. Mitochondrial donors will be providing their eggs in the same way as women donating eggs for fertility treatment. What should women donating their mitochondria be screened for? 4. Age may be an important consideration when selecting mitochondrial donors. Professional guidelines state that eggs for fertility treatment should not be taken from donors aged 36 or over. Do you think the proposed approach to apply the same age limit for women donating their mitochondria is appropriate? 5. The family limit refers to the number of families a single donor can help to create. Sperm and egg donors can donate to create a maximum number of 10 families. Do you think the proposed approach to apply the same 10 family limit to women donating their mitochondria is appropriate? Please provide reasons for your answer. 6. We set out the information that should be provided to fertility patients before consent to treatment is obtained. Before patients give their consent to treatment involving mitochondria donation, what information should clinics provide? 7. We set out the information that should be provided to prospective sperm, egg and embryo donors before their consent to donation is obtained. Before women give their consent to donating their mitochondria, what information should clinics provide? Regulating mitochondrial donation: seeking expert views 9
10 Follow-up studies Many experts have recommended that families using mitochondrial donation should be encouraged to take part in long-term follow-up studies in order to monitor any possible effects on children born and future generations. We propose that clinics should have in place a documented process for monitoring children born following mitochondrial donation, where patients have consented to follow up. The clinic should submit this information to us upon application to vary its licence to allow PNT and/or MST. This process should cover what links the clinic has with research groups or mitochondrial disease specialists, what follow up will involve (eg, the method and frequency of contact) and what information the clinic will provide to their patients about follow up. We propose introducing guidance that clinics should encourage their patients to take part in follow-up studies, whilst also acknowledging the rights of patients and their children not to participate in such studies. We also propose requiring clinics performing mitochondrial donation to submit any changes to this process to us on an annual basis. This should be submitted alongside an annual report setting out the clinic s progress on patient uptake of follow-up studies and (non-patient specific) information on the outcomes. If a clinic becomes aware that a child born following mitochondrial donation has been born with a mitochondrial disease, birth defect, or genetic abnormality (which may have been caused by MST or PNT), we will regard this as an adverse incident and the clinic is required by law to report this is to us. Question to consider We ve set out what we propose to do. Now we want to hear your views about follow-up studies. 8. Many experts recommend that families using mitochondrial donation techniques should be encouraged to take part in long-term follow-up studies to monitor any possible effects on children born and future generations. We propose that clinics must submit their process for following-up children to us. Do you think this approach is appropriate? What do you think this process should cover? Regulating mitochondrial donation: seeking expert views 10
Fill in this form if you are donating eggs and/or embryos created with your eggs for use in another person s mitochondrial donation
This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent regulator of fertility treatment and human embryo research. For more information about us, visit www.hfea.gov.uk.
More informationD D M M Y Y D D M M Y Y. For clinic use only (optional) MD PNT only (gender-neutral): version 1; 3 April 2017
This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent regulator of fertility treatment and human embryo research. For more information about us, visit www.hfea.gov.uk.
More informationMST and PNT allow eggs or embryos to be created for you containing your and your partner s nuclear genetic material D D M M Y Y D D M M Y Y
This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent regulator of fertility treatment and human embryo research. For more information about us, visit www.hfea.gov.uk.
More informationDirections given under the Human Fertilisation and Embryology Act 1990 as amended. Ref: 0006 Version: 4
Directions given under the Human Fertilisation and Embryology Act 1990 as amended Import and export of gametes and embryo Ref: 0006 Version: 4 These Directions are: GENERAL DIRECTIONS Sections of the Act
More informationSTEM CELL RESEARCH: MEDICAL PROGRESS WITH RESPONSIBILITY
STEM CELL RESEARCH: MEDICAL PROGRESS WITH RESPONSIBILITY A REPORT FROM THE CHIEF MEDICAL OFFICER S EXPERT GROUP REVIEWING THE POTENTIAL OF DEVELOPMENTS IN STEM CELL RESEARCH AND CELL NUCLEAR REPLACEMENT
More informationReproductive options for patients with mitochondrial DNA disease: using mitochondrial donation to prevent disease transmission
Reproductive options for patients with mitochondrial DNA disease: using mitochondrial donation to prevent disease transmission Emma Watson Newcastle NHS Highly Specialised Service for Rare Mitochondrial
More informationReproductive options for patients with mitochondrial DNA disease: using mitochondrial donation to prevent disease transmission
Reproductive options for patients with mitochondrial DNA disease: using mitochondrial donation to prevent disease transmission Emma Watson Newcastle NHS Highly Specialised Service for Rare Mitochondrial
More informationYour consent to disclosing identifying information
Your consent to disclosing identifying information HFEA CD form About this form This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent regulator of fertility
More informationReproductive technologies to prevent transmission of mitochondrial DNA disease. Louise Hyslop
Reproductive technologies to prevent transmission of mitochondrial DNA disease Louise Hyslop Mitochondria Produce > 90% of the energy our cells need Contain own DNA (mitochondrial DNA / mtdna) Multiple
More informationYour consent to donating your eggs
HFEA WD form (Gender-neutral version) Your consent to donating your eggs About this form This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent regulator
More informationHuman Fertilisation and Embryology Authority 10 Spring Gardens London SW1A 2BU t e w
Edition 8.0 First published October 2009 Revised April 2010, April 2011, October 2011, April 2012, October 2013, October 2014, April 2015, October 2015, July 2016, May 2017, October 2017 Human Fertilisation
More informationGuide to Good Practice in fertility cases
2018 Guide to Good Practice in fertility cases This Guidance was reviewed in March 2018. The law or procedure may have changed since that time and members should check the up-to-date position. Resolution
More informationMitochondrial Donation
Mitochondrial Donation Standard Note: SN/SC/6833 Last updated: 29 January 2015 Author: Dr Sarah Barber - Science and Environment Section Dr Peter Border Parliamentary Office of Science and Technology (POST)
More informationRecommended Interim Policy Statement 150: Assisted Conception Services
Southampton City Clinical Commissioning Group (CCG) took on commissioning responsibility for Assisted Conception Services from 1 April 2013 for its population and agreed to adopt the interim policy recommendations
More informationWest Hampshire Clinical Commissioning Group Board
West Hampshire Clinical Commissioning Group Board Date of meeting 25 July 2013 Agenda Item 9 Paper No WHCCG13/089 Priorities Committee Statement Assisted Conception/IVF Key issues An Interim Policy Statement
More informationPolicy statement. Commissioning of Fertility treatments
Policy statement Commissioning of Fertility treatments NB: The policy relating to commissioning of fertility treatments is unchanged from the version approved by the CCG in March 2017. The clinical thresholds
More informationWHAT YOU NEED TO KNOW ABOUT DONATING SPERM, EGGS OR EMBRYOS
14 February 2006 WHAT YOU NEED TO KNOW ABOUT DONATING SPERM, EGGS OR EMBRYOS Introduction The donation of sperm, eggs or embryos to help a couple have a child is one of the most generous gifts anyone can
More information15. Procuring, processing and transporting gametes and
15. Procuring, processing and transporting gametes and embryos Version 6.0 On this page: : Extracts from the HFE Act Directions HFEA guidance: Documented procedures: general Patient selection and procurement
More informationSHIP8 Clinical Commissioning Groups Priorities Committee (Southampton, Hampshire, Isle of Wight and Portsmouth CCGs)
SHIP8 Clinical Commissioning Groups Priorities Committee (Southampton, Hampshire, Isle of Wight and Portsmouth CCGs) Policy Recommendation 002: Assisted Conception Services Date of Issue: September 2014
More informationMen s consent to the use and storage of sperm or embryos for surrogacy
HFEA MSG form Men s consent to the use and storage of sperm or embryos for surrogacy About this form This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent
More informationYour consent to your sperm and embryos being used in treatment and/or stored (IVF and ICSI)
HFEA MT form (Gender-neutral version) Your consent to your sperm and embryos being used in treatment and/or stored (IVF and ICSI) About this form This form is produced by the Human Fertilisation and Embryology
More informationThe Regulation of Gene Editing in the UK
The Regulation of Gene Editing in the UK James Lawford Davies 29 April 2016 Paris for more information visit us at www.hempsons.co.uk HFEA Regulation: Research (1) Human Fertilisation and Embryology Act
More informationWomen s consent to the use and storage of eggs or embryos for surrogacy
Women s consent to the use and storage of eggs or embryos for surrogacy HFEA WSG form About this form This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent
More informationWHO ARE THE DONORS? - An HFEA Analysis of donor registrations and use of donor gametes over the last 10 years
WHO ARE THE DONORS? - An HFEA Analysis of donor registrations and use of donor gametes over the last 10 years Page 1 of 9 05/29501 Trends in the use of donor gametes (sperm and eggs) Donor assisted conception
More informationAccess to IVF. Help us decide Discussion paper. South Central Specialised Commissioning Group C - 1
Access to IVF Help us decide Discussion paper South Central Specialised Commissioning Group 1 C - 1 Access to IVF treatment Contents 1. Background 3 2. Developing a single policy for NHS South Central..4
More informationBromley CCG Assisted Conception Funding Form Checklist for Eligibility Criteria for NHS funding of Assisted Conception
Bromley CCG Assisted Conception Funding Form Checklist for Eligibility Criteria for NHS funding of Assisted Conception This form is for the use of administrators of Assisted Conception Units to notify
More informationDirector of Commissioning, Telford and Wrekin CCG and Shropshire CCG. Version No. Approval Date August 2015 Review Date August 2017
Commissioning Policy for In Vitro Fertilisation (IVF)/ Intracytoplasmic Sperm Injection (ICSI) within tertiary Infertility Services, in Shropshire and Telford and Wrekin Owner(s) Version No. Director of
More informationYour consent to the use of your sperm in artificial insemination
HFEA MGI form Your consent to the use of your sperm in artificial insemination About this form This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent regulator
More informationResearch Licence Renewal Inspection Report
Research Licence Renewal Inspection Report Project Title The vitrification of blastocysts following biopsy at the earlycleavage stage or blastocyst stage of embryo development A Pilot Study Research Licence
More informationIntroduction 4. Important information about consent to legal parenthood 7. Women s consent to treatment and storage form (IVF and ICSI) (WT form) 9
Introduction 4 Important information about consent to legal parenthood 7 Women s consent to treatment and storage form (IVF and ICSI) (WT form) 9 Men s consent to treatment and storage form (IVF and ICSI)
More informationWomen s consent to treatment and storage form (IVF and ICSI)
Women s consent to treatment and storage form (IVF and ICSI) HFEA WT form About this form This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent regulator
More informationINTRACYTOPLASMIC SPERM INJECTION
1 Background... 2 2 Male Factor Infertility... 2 3 ICSI... 3 4 Surgical sperm aspiration... 4 5 What is the chance of success?... 6 6 What are the risks?... 7 M Rajkhowa, October 2004 Authorised by V Kay
More informationYour consent to the storage of your eggs or sperm
Your consent to the storage of your eggs or sperm HFEA GS form About this form This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent regulator of fertility
More informationClinical Policy Committee
Clinical Policy Committee Commissioning policy: Assisted Conception Fertility assessment and investigations are commissioned where: A woman is of reproductive age and has not conceived after one (1) year
More informationFertility Policy. December Introduction
Fertility Policy December 2015 Introduction Camden Clinical Commissioning Group (CCG) is responsible for commissioning a range of health services including hospital, mental health and community services
More informationNuffield Council on Bioethics
This response was submitted to the call for evidence by the Nuffield Council on Bioethics on Emerging techniques to prevent inherited mitochondrial disorders: ethical issues between January 2012 and February
More informationWithdrawing your consent
HFEA WC form Withdrawing your consent About this form This form is produced by the Human Fertilisation and Embryology Authority (HFEA), the UK s independent regulator of fertility treatment and human embryo
More informationFriday, 13 January 2017 HFEA, 10 Spring Gardens, London SW1A 2BU
Friday, 13 January 2017 HFEA, 10 Spring Gardens, London SW1A 2BU Panel members Juliet Tizzard (Chair) Howard Ryan Trisram Dawahoo Members of the Executive Bernice Ash Secretary Director of Strategy & Corporate
More informationInformation For Egg Recipients
Egg Recipients Royal Devon and Exeter NHS Foundation Trust Information For Egg Recipients What is egg donation? Egg donation is a type of in-vitro fertilisation (IVF) treatment in which eggs are collected
More information17. Storage of gametes and embryos
17. Storage of gametes and embryos This guidance note contains: Mandatory requirements Extracts from the HFE Act 1990 (as amended) Extracts from licence conditions Reference to relevant HFEA Directions
More informationBlackpool CCG. Policies for the Commissioning of Healthcare. Assisted Conception
1 Introduction Blackpool CCG Policies for the Commissioning of Healthcare Assisted Conception 1.1 This policy describes circumstances in which NHS Blackpool Clinical Commissioning Group (CCG) will fund
More informationCommittee Paper SCAAC(05/09)01. ICSI guidance. Hannah Darby and Rachel Fowler
Committee Paper Committee: Scientific and Clinical Advances Advisory Committee Meeting Date: 12 May 2009 Agenda Item: 4 Paper Number: SCAAC(05/09)01 Paper Title: ICSI guidance Author: Hannah Darby and
More informationHaringey CCG Fertility Policy April 2014
Haringey CCG Fertility Policy April 2014 1 SUMMARY This policy describes the clinical pathways and entry criteria for Haringey patients wishing to access NHS funded fertility treatment. 2 RESPONSIBLE PERSON:
More informationPolicy updated: November 2018 (approved by Haringey and Islington s Executive Management Team on 5 December 2018)
Islington CCG Fertility Policy First approved: 29 January 2015 Policy updated: November 2018 (approved by Haringey and Islington s Executive Management Team on 5 December 2018) Introduction Islington CCG
More informationClinical Policy Committee
Northern, Eastern and Western Devon Clinical Commissioning Group South Devon and Torbay Clinical Commissioning Group Clinical Policy Committee Commissioning policy: Assisted Conception Fertility treatments
More informationTHE LAW - CONCEPTION USING DONOR EGGS OR SPERM
Assisted Conception Unit 11 th Floor, Tower Wing Guy s Hospital, Great Maze Pond London SE1 9RT Tel:.020 7188 2300 Fax: 020 7188 0490 THE LAW - CONCEPTION USING DONOR EGGS OR SPERM Introduction If you
More informationApproved January Waltham Forest CCG Fertility policy
Approved January 2015 Waltham Forest CCG Fertility policy Contents 1 Introduction 1 2 Individual Funding Requests 1 2.1 Eligibility criteria 1 2.2 Number of cycles funded 2 2.3 Treatment Pathway 3 Page
More informationNote: This updated policy supersedes all previous fertility policies and reflects changes agreed by BHR CCGs governing bodies in June 2017.
Fertility Policy 10 July 2017 Note: This updated policy supersedes all previous fertility policies and reflects changes agreed by BHR CCGs governing bodies in June 2017. Introduction BHR CCGs are responsible
More informationSperm Donation - Information for Donors
Sperm Donation - Information for Donors The donation of sperm to help someone to have a child is one of the most generous gifts anyone can give. Many donors feel a sense of pride, knowing the joy they
More information[Act on Artificial Fertilisation and use of Human Gametes and Embryos for Stem-Cell Research] 1) No. 55/1996 1) Act No. 27/2008, Article 9
[Act on Artificial Fertilisation and use of Human Gametes and Embryos for Stem-Cell Research] 1) No. 55/1996 1) Act No. 27/2008, Article 9 as amended by Act No. 65/2006, Act No. 27/2008, Act No. 54/2008,
More informationFriday, 22 September 2017 HFEA, 10 Spring Gardens, London SW1A 2BU
Friday, 22 September 2017 HFEA, 10 Spring Gardens, London SW1A 2BU Panel members Hannah Verdin (Chair) Howard Ryan Jessica Watkin Head of Regulatory Policy Report Developer Policy Manager Members of the
More informationNot Unsafe Does Not Equal Safe An Evaluation of the HFEA s report on MST and PNT
Not Unsafe Does Not Equal Safe An Evaluation of the HFEA s report on MST and PNT I. Introduction Aditi Shah On June 3, 2014, the United Kingdom s Human Fertility and Embryo Authority (HFEA) prepared an
More informationFriday, 25 August 2017 HFEA, 10 Spring Gardens, London SW1A 2BU
Friday, 25 August 2017 HFEA, 10 Spring Gardens, London SW1A 2BU Panel members Hannah Verdin (Chair) Anna Coundley Howard Ryan Head of Regulatory Policy Information Access and Policy Manager Report Developer
More informationHALTON CLINICAL COMMISSIONING GROUP NHS FUNDED TREATMENT FOR SUBFERTILITY. CONTENTS Page
HALTON CLINICAL COMMISSIONING GROUP NHS FUNDED TREATMENT FOR SUBFERTILITY CONTENTS Page 1. INTRODUCTION 2 2. GENERAL PRINCIPLES 2 3. DEFINITION OF SUBFERTILITY AND TIMING OF ACCESS TO TREATMENT 3 4. DEFINITION
More informationSt Helens CCG NHS Funded Treatment for Subfertility Policy 2015/16
St Helens CCG NHS Funded Treatment for Subfertility Policy 2015/16 1 Standard Operating Procedure St Helens CCG NHS Funded Treatment for Sub Fertility Policy Version 1 Implementation Date May 2015 Review
More informationGOVERNING BOARD. Assisted Conception (IVF): Review of access criteria. Date of Meeting 21 January 2015 Agenda Item No 13. Title
GOVERNING BOARD Date of Meeting 21 January 2015 Agenda Item No 13 Title Assisted Conception (IVF): Review of access criteria Purpose of Paper The SHIP (Southampton, Hampshire, Isle of Wight and Portsmouth)
More informationASSISTED CONCEPTION NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA & POLICY GUIDANCE
ASSISTED CONCEPTION NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA & POLICY GUIDANCE Version 1.0 Page 1 of 11 MARCH 2014 POLICY DOCUMENT VERSION CONTROL CERTIFICATE TITLE Title: Assisted Conception
More informationUnit B2, B2.7. Cell division and inheritance. Stage 1. Ovary. Cell Q. Cell P. Cell R. Cell S. 7 Embryo A B C
Cell division and inheritance 1. A woman gives birth to triplets. Two of the triplets are boys and the third is a girl. The triplets developed from two egg cells released from the ovary at the same time.
More informationGOVERNING BODY MEETING IN VITRO FERTILISATION (IVF) AND ASSISTED CONCEPTION CONSULTATION. Matt Rangué, Chief Nurse, NHS Southend CCG
AGENDA ITEM 5. GOVERNING BODY MEETING IN VITRO FERTILISATION (IVF) AND ASSISTED CONCEPTION CONSULTATION Date of the meeting 1 st February 2018 Author Sponsoring Governing Body Member Purpose of Report
More informationTHE CENTER FOR ADVANCED REPRODUCTIVE SERVICES (CARS) (The Center) CONSENT TO PERFORM THERAPEUTIC DONOR INSEMINATION WITH IDENTIFIED DONOR SPERM
THE CENTER FOR ADVANCED REPRODUCTIVE SERVICES (CARS) (The Center) CONSENT TO PERFORM THERAPEUTIC DONOR INSEMINATION WITH IDENTIFIED DONOR SPERM Partner #1 Last Name (Surname): Partner #1 First Name: Partner
More informationInformation about The Storage of Sperm, Eggs and Embryos before starting Chemo or Radiotherapy Treatment
Information about The Storage of Sperm, Eggs and Embryos before starting Chemo or Radiotherapy Treatment Assisted Conception Services Glasgow Royal Infirmary 84 Castle Street Glasgow G4 0SF Telephone:
More informationCOMMISSIONING POLICY FOR IN VITRO FERTILISATION (IVF)/ INTRACYTOPLASMIC SPERM INJECTION (ICSI) WITHIN TERTIARY INFERTILITY SERVICES V2.
COMMISSIONING POLICY FOR IN VITRO FERTILISATION (IVF)/ INTRACYTOPLASMIC SPERM INJECTION (ICSI) WITHIN TERTIARY INFERTILITY SERVICES V2.3 2017 Agreed at Cannock Chase CCG Signature: Designation: Chair of
More informationHuman Fertilisation and Embryology Authority
response to the Human Fertilisation and Embryology Authority public consultation on The 7 th Edition of the Code of Practice December 2006 This document represents the British Fertility Society (BFS) response
More informationThe Gay Woman s Guide to Becoming a Mom PATH2PARENTHOOD. path2parenthood.org
The Gay Woman s Guide to Becoming a Mom PATH2PARENTHOOD path2parenthood.org For lesbians, there are a number of viable routes that can be considered when achieving motherhood is the goal. Whether you are
More informationFriday, 25 August 2017 HFEA, 10 Spring Gardens, London SW1A 2BU
Friday, 25 August 2017 HFEA, 10 Spring Gardens, London SW1A 2BU Panel members Hannah Verdin (Chair) Anna Coundley Howard Ryan Head of Regulatory Policy Information Access and Policy Manager Report Developer
More informationT39: Fertility Policy Checklist
Patient Name: Address: Date of Birth: NHS Number: Consultant/Service to whom referral will be made: Institution Lifestyle Information Latest BMI: Latest BP: Smoking Status: Has the patient been referred
More informationCONSENT In Vitro Fertilization, Intracytoplasmic Sperm Injection, Assisted Hatching, and Embryo Cryopreservation/Disposition
CONSENT In Vitro Fertilization, Intracytoplasmic Sperm Injection, Assisted Hatching, and Embryo Cryopreservation/Disposition Please Print PATIENT Name: Patient DOB: _/ _/ Patient eivf number: PARTNER Name
More informationFertility Services Commissioning Policy (Level 3)
Fertility Services Commissioning Policy (Level 3) Author: Karin Bryant (Norwich CCG) has coordinated the refresh of policy Version No: V54 Policy Effective from: TBC Review Date: TBC This policy replaces
More informationCONSENT FOR ASSISTED REPRODUCTION In Vitro Fertilization, Intracytoplasmic Sperm Injection, Assisted Hatching, Embryo Freezing and Disposition
CONSENT F ASSISTED REPRODUCTION In Vitro Fertilization, Intracytoplasmic Sperm Injection, Assisted Hatching, Embryo Freezing and Disposition Please read the following consent carefully. If you do not understand
More informationHFEA Executive Licensing Panel Meeting 5 September 2014 Finsbury Tower, Bunhill Row, London, EC1Y 8HF
Minutes Item 1 HFEA Executive Licensing Panel Meeting 5 September 2014 Finsbury Tower, 103-105 Bunhill Row, London, EC1Y 8HF Centre 0030 (Herts and Essex Fertility Centre) Renewal Treatment & Storage Inspection
More informationGuidelines. for the. Storage, Use, and Disposal. of Sperm. from a Deceased Man. February 2000
Guidelines for the Storage, Use, and Disposal of Sperm from a Deceased Man February 2000 Prepared by the National Ethics Committee on Assisted Human Reproduction (NECAHR) c/o Ministry of Health PO Box
More informationEthical guidelines on the use of assisted reproductive technology in clinical practice and research
Ethical guidelines on the use of assisted reproductive technology in clinical practice and research AUSTRALIAN HEALTH ETHICS COMMITTEE Endorsed by NHMRC for public release in September 2004 September 2004
More informationTHE CENTER FOR ADVANCED REPRODUCTIVE SERVICES (CARS) (The Center) CONSENT TO PERFORM THERAPEUTIC DONOR INSEMINATION WITH ANONYMOUS DONOR SPERM
THE CENTER FOR ADVANCED REPRODUCTIVE SERVICES (CARS) (The Center) CONSENT TO PERFORM THERAPEUTIC DONOR INSEMINATION WITH ANONYMOUS DONOR SPERM Partner #1 Last Name (Surname): Partner #1 First Name: Partner
More informationIVF. NHS North West London CCGs
IVF NHS North West London CCGs Commissioning Policy for In Vitro Fertilisation (IVF)/ Intracytoplasmic Sperm Injection (ICSI) within tertiary Infertility Services Adopted by NWL CCGs to be effective from
More informationPublic consultation: Seeking your views on IVF
Public consultation: Seeking your views on IVF Introduction We (NHS Bury Clinical Commissioning Group (CCG)) are seeking views from patients registered with a Bury GP practice, Bury health care professionals
More informationCOMMISSIONING POLICY FOR IN VITRO FERTILISATION (IVF)/ INTRACYTOPLASMIC SPERM INJECTION (ICSI) WITHIN TERTIARY INFERTILITY SERVICES
COMMISSIONING POLICY FOR IN VITRO FERTILISATION (IVF)/ INTRACYTOPLASMIC SPERM INJECTION (ICSI) WITHIN TERTIARY INFERTILITY SERVICES Version number V2.3 Responsible individual Author(s) Barry Weaver Trish
More informationCOMMISSIONING POLICY. Tertiary treatment for assisted conception services
Final Version COMMISSIONING POLICY Tertiary treatment for assisted conception services Designated providers for patients registered with a Worcestershire GP BMI The Priory Hospital, Birmingham - 1 - Commissioning
More informationFERTILITY SERVICE POLICY
FERTILITY SERVICE POLICY Page 1 of 8 FERTILITY SERVICE POLICY Please note that all Clinical Commissioning policies are currently under review and elements within the individual policies may have been replaced
More informationEgg sharing (Donor) Information for Patients and Partners
Egg sharing (Donor) Information for Patients and Partners Date of Issue: 29/06/2018 Doc 392 Issue 10 1 of 10 Who is this leaflet about and who is it for? This leaflet is produced to inform couples considering
More informationNHS FUNDED TREATMENT FOR SUBFERTILITY. ELIGIBILITY CRITERIA POLICY GUIDANCE/OPTIONS FOR CCGs
NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA POLICY GUIDANCE/OPTIONS FOR CCGs CONTENTS Page 1. INTRODUCTION 2 2. GENERAL PRINCIPLES 2 3. DEFINITION OF SUBFERTILITY AND TIMING OF ACCESS TO
More informationHuman Fertilisation and Embryology Authority. Minutes of the Executive Licensing Panel
Human Fertilisation and Embryology Authority Minutes of the Executive Licensing Panel Meeting held at HFEA, Finsbury Tower, 103-105 Bunhill Row, London, EC1Y 8HF on 27 February 2015 Minutes item no. 1
More informationEast and North Hertfordshire CCG. Fertility treatment and referral criteria for tertiary level assisted conception
East and North Hertfordshire CCG Fertility treatment and referral criteria for tertiary level assisted conception December 2015 1 1. Introduction This policy sets out the entitlement and service that will
More informationAdverse incidents in fertility clinics: lessons to learn
Adverse incidents in fertility clinics: lessons to learn January-December 2014 www.hfea.gov.uk Adverse incidents in fertility clinics: lessons to learn Human Fertilisation and Embryology Authority 3 Contents
More informationFertility treatment and referral criteria for tertiary level assisted conception
Fertility treatment and referral criteria for tertiary level assisted conception Version Number Name of Originator/Author Cross Reference V2 East of England Consortium Commissioning Policy for Fertility
More informationREPUBLIC OF LITHUANIA LAW ON DONATION AND TRANSPLANTATION OF HUMAN TISSUES, CELLS AND ORGANS. 19 November 1996 No I-1626 Vilnius
REPUBLIC OF LITHUANIA LAW ON DONATION AND TRANSPLANTATION OF HUMAN TISSUES, CELLS AND ORGANS 19 November 1996 No I-1626 Vilnius (As last amended on 12 May 2016 No XII-2344) CHAPTER I GENERAL PROVISIONS
More informationAssisted Conception Policy
Assisted Conception Policy NHS Eligibility Criteria for assisted conception services (excluding In vitro fertilisation (IVF) Intracytoplasmic sperm injection (ICSI) treatment) for people with infertility
More informationRound robin summary - March 2012 Co-payment for unlicensed drug Egg donation Recruitment and training of Lay members
Round robin summary - Co-payment for unlicensed drug Egg donation Recruitment and training of Lay members In January we received three round robin requests to the Network. Below are the requests followed
More informationWOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR THAWING AND TRANSFER OF CRYOPRESERVED EMBRYOS. I and
*40668* 40668 WOMEN & INFANTS HOSPITAL Providence, RI 02905 CONSENT FOR THAWING AND TRANSFER OF CRYOPRESERVED EMBRYOS FOR inpatients: affix patient label OR I and (Print Patient s name) (Print Partner
More information[p.1 of Form (8)] SAMP Consent to Designated Donation of Sperm. 1. I (name of donor) (hereinafter
[p.1 of Form (8)] SAMP Consent to Designated Donation of Sperm Part I DONOR S CONSENT 1. I (name of donor) (hereinafter (Surname, Given s) (ID No.) called the Donor ), DO HEREBY CONSENT to donating my
More informationTwo commissioning alternatives are presented for consideration:
Item Number: 8 NHS VALE OF YORK CLINICAL COMMISSIONING GROUP GOVERNING BODY MEETING Meeting Date: 4 April 2013 Report Sponsor: Mark Hayes Chief Clinical Officer Report Author: North Yorkshire and Humber
More informationSubmission to the Commission on Assisted Human Reproduction December 2001
Submission to the Commission on Assisted Human Reproduction December 2001 We believe that the following core principles should govern public policy related to Assisted Human Reproduction: 1. Assisted human
More informationFertility Services Commissioning Policy
Fertility Services Commissioning Policy Author: Commissioning Team Version No: Two Policy Effective From: 29 September 2016 Review Date: September 2017 Policy Amendment: 02 August 2017 Document Reader
More informationFemale Patient Name: Social Security # Male Patient Name: Social Security #
Female Patient Name: Social Security # Male Patient Name: Social Security # THE CENTER FOR HUMAN REPRODUCTION (CHR) ILLINOIS/NEW YORK CITY * ASSISTED REPRODUCTIVE TECHNOLOGIES PROGRAM (A.R.T.) CRYOPRESERVATION
More informationNorth Staffordshire Clinical Commissioning Group. Infertility and Assisted Reproduction Commissioning Policy and Eligibility Criteria
North Staffordshire Clinical Commissioning Group Infertility and Assisted Reproduction Commissioning Policy and Eligibility Criteria Policy Infertility and Assisted Reproduction Commissioning Policy and
More informationExecutive Licensing Panel - minutes
Executive Licensing Panel - minutes Centre 0342 (Concept Fertility) Renewal Inspection Report Friday, 27 January 2017 HFEA, 10 Spring Gardens, London SW1A 2BN Panel members Juliet Tizzard (Chair) Paula
More informationFertility treatment in trends and figures
Fertility treatment in 2010 trends and figures Contents Page No: Foreword by the Chair of the HFEA 3 Summary 4 Section 1: Overview How many fertility clinics were there in the UK in 2010? 6 How many women
More informationExecutive Summary for Executive Licensing Panel 20 May Dr Kamal Ahuja. Follow-up inspection 14 April 2010
Summary for Licensing Panel 20 May 2010 Centre number 0011 Centre name The London Sperm Bank Person Responsible Dr Kamal Ahuja Background Follow-up inspection 14 April 2010 1. The London Sperm Bank underwent
More informationPaper. Donation review conditional donation. Hannah Darby, Policy Manager. Decision
Paper Paper Title: Donation review conditional donation Paper Number: ELAC (06/11)2 Meeting Date: 8 June 2011 Agenda Item: 7 Author: For information or decision? Recommendation to the Annexes Hannah Darby,
More informationMonday, 22 January 2018 HFEA, 10 Spring Gardens, London SW1A 2BU
Monday, 22 January 2018 HFEA, 10 Spring Gardens, London SW1A 2BU Panel members Members of the Executive External adviser Caylin Joski-Jethi (Chair) Jessica Watkin Helen Crutcher Bernice Ash Nana Gyamfi
More informationCEL 09 (2013) 15 May Dear Colleague
Director General Health and Social Care and Chief Executive NHS Dear Colleague Provision of Infertility Services in Scotland (updated IVF criteria) As you know a National Infertility Group was convened
More information